Jonathan Stern

Hims House

Business EN ↓ 88 episodes

Hims House is the ultimate podcast for Hims & Hers investors. Hosted by Jonathan Stern and Patrick Lester, Hims House breaks down all the key questions shaping $HIMS — from telehealth and pharma to GLP-1s, compounding, and the future of healthcare. New episodes every week. himshouse.substack.com

Be sure to visit the podcast's website and support the creator: himshouse.substack.com

Author

Jonathan Stern

Category

Business

Podcast website

himshouse.substack.com

Latest episode

Nov 18, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

🚨 EXCLUSIVE: Max Marchione, Superpower CEO, on the peptides launch and how he's thinking about Hims 18.11.2026

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com/himshouse In episode 88, Jonathan Stern talks with Max Marchione, co-founder and CEO of Superpower, back for his third appearance on the show. Two days after HHS cleared the way for pharmacies to make BPC-157, TB-500, and four other peptides, Superpower started taking pre-orders. We get into pricing...

Hims Q3 earnings recap: "Most disappointing quarter so far" + why Brian Birnbaum is still bullish 12.11.2026

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com/himshouse In episode 87, Jonathan Stern talks with Brian Birnbaum, "The Psycho Analyst," after a brutal week for the stock. We discuss Q3 earnings, which saw subscribers fall for the first time in company history. Plus, Ro disclosed $3B in annual recurring revenue, now ahead of Hims in the...

🚨 BPC-157 and five other peptides just got the green light: "It's going to be a knife fight" 02.11.2026

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com/himshouse Subscribe to Hims House: https://himshouse.com Follow us: https://x.com/himshouse https://x.com/jonathanrstern https://x.com/jefftangx In episode 86, Jonathan Stern talks with Jeff Tang, a Y Combinator founder who sold his longevity meal prep company to Bryan Johnson and now hosts Peptide...

Why Hims & Hers may be the most asymmetric opportunity in the entire stock market 29.10.2026

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com/himshouse Follow us: https://x.com/himshouse https://x.com/jonathanrstern https://x.com/TravisHoium https://youtube.com/@asymmetricinvesting https://asymmetric-investing.beehiiv.com In episode 85, Jonathan Stern talks with Travis Hoium, founder of Asymmetric Investing, who started buying Hims in spr...

Why payment processors treat peptides as "riskier than gambling", per gray-market peptide CEO 20.10.2026

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com FDA warning letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026 In episode 84, Jonathan Stern talks with Zak David, founder of Peptide Partners, one of the largest research-peptide sellers in the US. This is...

Are Peptides Coming By End Of Year? 15.10.2026

Thanks to our partners: Superpower - https://superpower.com CareValidate - https://carevalidate.com In episode 83, Jonathan Stern talks with Scott Brunner, CEO of the Alliance for Pharmacy Compounding, the trade group for more than 600 compounding businesses, about the WaPo report that the administration may let pharmacies sell certain peptides before a formal rule is finished. Brunner says he thi...

Brazil's 2nd-largest telehealth CEO on how Hims & Hers should enter Brazil 🇧🇷 08.10.2026

Thanks to our partner: Superpower - https://superpower.com In episode 82, Jonathan Stern talks with Abrahão Fecury, co-founder and CEO of Eles & Elas, a Brazilian telehealth company built on the Hims playbook and now at about R$4.5 million (~$1 million USD) in annual revenue, growing about +10% a month. Weight loss is about 70% of that (compounded tirzepatide) at a 54% gross margin, with hair...

Finnrick CEO on gray market peptides, fake bodega vials, and China's manufacturing prowess 01.10.2026

Thanks to our partner:Superpower - https://superpower.com

OpenLoop CEO: the peptide gray market is 2-3x bigger than analyst estimates, likely $6-8 billion 16.09.2026

Thanks to our partner:Superpower - https://superpower.com In episode 80 of Hims House, Jonathan Stern talks with Dr. Jon Lensing, co-founder and CEO of OpenLoop, the white-label company that runs telehealth behind the scenes for other brands. Lensing started OpenLoop out of the University of Iowa's medical school and says the platform will see more than 8 million patients this year and treat m...

HIMS stock token hit $132 on Robinhood over the weekend due to ... $BONER coin?! 😳 03.09.2026

Thanks to our partner:Superpower - https://superpower.com 🚨 WARNING: This is not a typical Hims House podcast! I wanted to do this interview because what happened on Robinhood Chain this weekend directly affected $HIMS -- and I think Hims investors should at minimum understand what happened. Jonathan Stern talks with Eric, an Ethereum OG and the world's largest $BONER holder, and Yoni, co-founder...

🚨 THE FTC SUES HIMS & HERS -- Full breakdown with Gaston Kroub 02.09.2026

Thanks to our partner:Superpower - https://superpower.com Jonathan Stern talks with Gaston Kroub, founding partner of K2K Law, registered patent attorney, and Hims House's resident legal expert on his third appearance, about the FTC's July 29 federal complaint against Hims & Hers. Kroub calls the filing a public "marketing document" aimed at a quick settlement and ranks three...

Bijan Salehizadeh - Eli Lilly's War on Compounded GLP-1s, Peptides, Retatrutide, and Hims vs Ro 26.08.2026

Thanks to our partner:Superpower - https://superpower.com In episode 77, Jonathan Stern talks with Dr. Bijan Salehizadeh -- physician and managing director of NaviMed Capital, former pharma venture investor, founding investor in Auris Health. Bijan holds no position in HIMS. The conversation opens on the FDA: why Heidi Overton is "moldable clay," her 30-40% confirmation odds, and why pha...

Enhanced Group CEO: Hot peptide summer is coming — but likely not till 2027 07.08.2026

Thanks to our partner:Superpower - https://superpower.com Max's recent essays on peptides: https://maximilianbmartin.substack.com/p/six-peptides-one-signal-washington https://maximilianbmartin.substack.com/p/the-peptide-moment-is-here-enhanced In episode 76 of Hims House, Jonathan Stern hosts Maximilian Martin, CEO of Enhanced Group ( $ENHA ), the newly public company behind the Enhanced Games...

🚨 FDA committee votes "YES" on 6 of 7 peptides — here's what happens next, with Dr. Alex Tatem 27.07.2026

Thanks to our partner:Superpower - https://superpower.com In episode 75 of Hims House, Jonathan Stern talks with Dr. Alex Tatem, a board-certified urologist who has worked with peptides for 12 years and paid his own way to Silver Spring, MD, to testify on all 7 peptides before the FDA's Pharmacy Compounding Advisory Committee. The panel overruled the FDA's own scientists and recommended si...

The FDA peptides vote is days away. This insider expects approval 15.07.2026

Thanks to our partner:Superpower - https://superpower.com In episode 74, Jonathan Stern sits down with Dr. Jesse Morse, a board-certified family and sports medicine physician, longtime peptide prescriber who helped assemble safety evidence for the upcoming PCAC review. They discuss the FDA briefing recommending against adding seven peptides to the 503A bulks list and how the 2023 restrictions push...

Ryan MacDonald: Peptides could be a $30B+ market, and Hims is positioned to win meaningful share 07.07.2026

In Hims House episode 73, Jonathan Stern talks with Needham’s Ryan MacDonald, the lead Hims & Hers analyst with a $35 price target and Buy rating. They break down the latest peptide news, how the FDA/PCAC process actually works, and why peptides may be more of a 2027 revenue story for major telehealth platforms like Hims. They also size the peptide opportunity, debate Hims’ potential share, an...

🚨 EXCLUSIVE: Hims board member David Wells on why he bought $1.2M of Hims 01.07.2026

In episode 72 of Hims House, Jonathan Stern interviews David Wells, Hims board member and former Netflix CFO, about his recent $1.2 million open-market purchase of Hims shares. Wells explains why he believes the company is at an inflection point after the Novo dispute and why the market may be missing the larger healthcare platform story. He discusses Hims’ mission, the broken cost and access stru...

Hedge funder Ignacio Canto on retail cults, Hims as Costco + Netflix, and why Hims has 10x upside 24.06.2026

In Hims House episode 71, Jonathan Stern sits down with hedge fund manager Ignacio Canto -- founder & portfolio manager at X-Square Capital, which held over 420k Hims shares as of Q1. Canto traces his interest back years, through personal product discovery and his late father's perspective as a urologist, and frames Hims as a platform business attacking a broken, expensive, and slow healthcare...

Hedge fund manager Imran Khan bought more Hims at its most hated moment -- here's why 16.06.2026

In Hims House episode 70, Jonathan Stern sits down with hedge fund manager Imran Khan, founder and CIO of Proem Asset Management and a Hims shareholder (110,000 shares as of March 31). Khan lays out his investment framework -- long-term growth potential, execution track record -- and argues that Hims' core asset is its loyal customer base and its ability to stack new products and services on t...

Cremieux - Half of America could be on GLP-1s by 2030 (and why peptides are probably overhyped) 10.06.2026

In episode 69 of Hims House, Jonathan Stern welcomes back researcher and data analyst Cremieux to take stock of the GLP-1 and peptides market. Cremieux points to Epic's new EHR dashboard as the best live read on adoption, backing estimates that roughly one in eight adults are on GLP-1s and one in five have tried them -- with cost and stigma holding back uptake until semaglutide generics arrive...

Sagar & Sahil Chopra - Founders of Empower Sleep on AI-powered sleep care and the Hims opportunity 26.05.2026

In episode 68, Jonathan Stern hosts Sagar and Sahil Chopra, founders of Empower Sleep, to unpack why sleep care is still fragmented, slow, and overly dependent on single-night testing. They explain how Empower uses multi-night diagnostics, wearable integrations, coaches, and clinicians to build a fuller picture of what is actually driving poor sleep. They also discuss how weight loss, GLP-1s, alco...

Eli Dorf (Bask Health) - What is Hims’ moat if anyone can launch a telehealth startup overnight? 19.05.2026

In episode 67 of Hims House, Jonathan Stern hosts Eli Dorf, founder and president of Bask Health. Bask provides the operating infrastructure for telehealth brands to launch quickly, choose pharmacy and clinical partners, route patients, process payments, and fulfill medications. Eli explains why outsourced infrastructure can let small teams scale fast, what Medvi’s rise reveals about the telehealt...

Brian Birnbaum - Hims & Hers Q1 earnings breakdown and the long-term bull case for Hims 13.05.2026

Thanks to our partner: Superpower - https://superpower.com Subscribe to Hims House: https://himshouse.com Brian's excellent essay on Hims: https://thepsychoanalyst.substack.com/p/protect-this-hims-house Follow us: https://x.com/himshouse https://x.com/jonathanrstern https://x.com/therealbirnbaum In episode 66 of Hims House, Jonathan Stern hosts Brian Birnbaum, “The Psycho Analyst,” for a post-...

Mansi Hukmani - The #1 peptide Substacker on peptide culture, supply-chain race & coming gold rush 30.04.2026

In episode 65 of Hims House, Jonathan Stern talks with Mansi Hukmani, founder of Chief Longevity Officer, about how peptide culture moved from biohacker circles into the next big frontier for telehealth. Mansi explains how New York, San Francisco, London, and Dubai each approach longevity culture differently, and why distrust in traditional healthcare has helped peptides feel more like a movement...

Enhanced Games - "We're ready to go" on peptides, prepping $1.2B SPAC in May 27.04.2026

In Hims House episode 64, Jonathan Stern hosts Max Martin & Christian Angermayer, co-founders of Enhanced, ahead of their inaugural May 24 Las Vegas games featuring track, swimming, weightlifting, and a deadlift showdown between Thor Björnsson and Mitchell Hooper. They argue that banning PEDs drives unsafe, hidden use and that openly allowing FDA-approved substances under medical supervision,...

Listen to the Hims House podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.